An ROS-responsive, RGC-targeted nanotherapeutic strategy with a TRPV4 antagonist restores autophagic flux and protects RGCs in a rat model of chronic ocular hypertension Authors: Jiarun Song, Xueqi Zhang, Pengwei Huang, Hui Li, Wenhui Liu, Liyan Wang, Ruiqing Wang, Zhuoran Ye, Jingxin Zhang, Zhiyue Zhang, Hui Guo Published: 2026 ABSTRACT BackgroundGlaucoma leads to progressive degeneration of retinal ganglion cells (RGCs), highlighting an urgent need for neuroprotective strategies beyond intraocular pressure reduction. Our previous work demonstrated that activation of the mechanosensitive channel Transient Receptor Potential Vanilloid 4 (TRPV4) contributes to RGC apoptosis in a chronic ocular hypertension (COH) rat model, and that the TRPV4 antagonist HC-067047 exhibits neuroprotective potential. However, its mechanism of action remains unclear, and its therapeutic efficacy is limited by poor RGC targeting, rapid clearance, and associated toxicity.ResultsIn this study, we developed an RGC-targeted and reactive oxygen species (ROS)-responsive drug delivery system by combining cholera toxin subunit B (CTB)-mediated selective uptake with an ROS-cleavable polymeric shell encapsulating HC-067047. The nanoparticles were efficiently internalized by RGCs and released the drug specifically in the COH-induced high-ROS microenvironment. Mechanistically, COH-induced TRPV4 activation led to calcium dysregulation and impaired autophagic flux—a key process linked to RGC vulnerability. Inhibition of TRPV4 via this targeted delivery system restored autophagic flux and significantly reduced COH-induced RGC injury.ConclusionsThese findings identify TRPV4-mediated autophagy dysregulation as a critical mechanism in glaucomatous damage and propose a precise, controlled-release nanotherapeutic strategy for the treatment of glaucoma.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-026-04661-2. Background Glaucoma is a neurodegenerative disorder characterized by progressive retinal ganglion cell (RGC) loss, thinning of the retinal nerve fiber layer, and visual function deterioration [1]. It is estimated that the number of individuals with glaucoma will exceed 100 million by 2040 [2]. The mechanisms underlying RGC death in glaucoma are multifactorial and incompletely understood, involving oxidative stress, excitotoxicity, mitochondrial dysfunction, and neuroinflammation [3–7]. Elevated intraocular pressure (IOP) is considered the most substantial risk factor for glaucoma [8]; however, in clinical practice, progressive optic neuropathy may still occur in some patients, even when IOP is adequately controlled [3, 6]. Therefore, beyond lowering IOP, there is an urgent requirement to explore and develop therapeutic strategies that directly preserve RGCs and maintain their functional integrity. Transient receptor potential vanilloid 4 (TRPV4) is a non-selective cation channel widely expressed in various human tissues that can be activated by multiple physical and chemical stimuli [9, 10]. In ocular tissues, TRPV4 is abundantly expressed in cornea, trabecular meshwork, and retina, and is particularly enriched in RGCs [11, 12]. Previous studies revealed that TRPV4 expressed in mouse α-RGCs is highly sensitive to fluctuations in IOP [12, 13]. Excessive TRPV4 activation can induce intracellular calcium (Ca2+) overload and trigger downstream signaling cascades, thereby contributing to neuronal damage and degenerative changes in various optic neuropathies [11, 12, 14]. Previous research from our team and other authors revealed that the TRPV4 antagonist HC-067047 attenuated RGC injury in chronic ocular hypertension (COH) models, suggesting that TRPV4 inhibition may represent a promising neuroprotective approach for glaucoma [15]. However, the underlying mechanisms remain unclear. Moreover, the intraocular targeted delivery and controlled release of small-molecule compounds such as HC-067047 face numerous challenges. Autophagy is an essential degradative pathway that maintains cellular homeostasis and exerts a classical "double-edged sword" effect on neurons [16–18]. Under stress or injury, moderate autophagic flux activation facilitates the clearance of damaged proteins and dysfunctional organelles, particularly mitochondria, thereby alleviating oxidative stress, reducing the metabolic burden, and preserving intracellular homeostasis [19–22]. However, insufficient initiation of autophagy or impairment of lysosomal degradation leads to disrupted autophagic flux and intracellular accumulation of aberrant autophagic structures and substrates, which can activate stress-related and pro-apoptotic signaling pathways [16, 23–25]. Currently, there is controversy over whether COH-induced RGC apoptosis is directly associated with autophagic dysfunction. Some evidence suggested that overactivated autophagy might exacerbate RGC death in glaucoma [26, 27]; however, other findings indicated that insufficient autophagy rendered RGCs more vulnerable to glaucoma-related insults [28, 29]. TRPV4-mediated autophagy regulation has been implicated in various disease models. TRPV4 activation can markedly disturb intracellular Ca2+ homeostasis, thereby influencing key signaling axes that are crucial for autophagy initiation and may indirectly modify autophagic flux by modulating lysosomal function or participating in transcriptional regulation [30, 31]. However, under COH conditions, it remains unclear whether TRPV4 participates in modulating autophagy in RGCs, whether its regulatory role occurs at the initiation or degradation stage of autophagy, and whether these autophagic alterations ultimately determine RGC apoptosis or survival. Although we have confirmed that the TRPV4 antagonist HC-067047 attenuated RGC injury and played a neuroprotective role in COH rat models, the intraocular targeted delivery and controlled release of this small-molecule compound still have multiple limitations. Due to the blood-aqueous barrier and the blood-retinal barrier, together with the inherently poor corneal penetration of the drug, topical administration allowed only a very small HC-067047 amount to reach the retina [32, 33]. Furthermore, although intravitreal injections can deliver the drug directly into the eye, they carry several drawbacks, including potential toxicity to non-target ocular tissues, limited intraocular retention time, low uptake efficiency by target cells, and increased risks of endophthalmitis and tissue injury associated with repeated injections [33, 34]. To overcome the diffusion gradient within the vitreous cavity, relatively high doses are often required, which may result in transiently excessive local drug concentrations after injection, subsequently triggering immune-related toxicity or inflammatory responses [35]. These factors collectively constrain the translational development and clinical implementation of TRPV4 inhibition-based neuroprotective strategies for glaucoma. To overcome these limitations, we designed a targeted nanodelivery system that selectively homes to RGCs and releases the TRPV4 antagonist specifically within the injury microenvironment. We employed cholera toxin subunit B (CTB) as a surface ligand, leveraging its high specificity for RGC labeling in the retina and minimal uptake by non-neuronal tissues to achieve precise nanoparticle delivery [36]. Furthermore, based on prior studies and our preliminary data showing significantly elevated reactive oxygen species (ROS) levels in the retinal ganglion cell layer (GCL) of the COH model [5], we incorporated an ROS-responsive controlled-release mechanism. This allows drug release to be triggered specifically by the pathological microenvironment. The system is based on an amphiphilic block copolymer formed by the self-assembly of the hydrophobic, ROS-responsive monomer 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzyl acrylate (Hb) with the hydrophilic N, N-dimethylacrylamide (DMA). Under high ROS conditions, the polymer backbone undergoes selective cleavage, releasing the encapsulated TRPV4 antagonist and enabling a pathology-triggered drug delivery pattern. In this study, we constructed an RGC-targeted and ROS-responsive controlled-release drug delivery system and further studied the autophagy role in RGCs under COH conditions and whether antagonizing TRPV4 exerted a neuroprotective effect by regulating the autophagic process (Scheme 1). Our findings offer novel theoretical insights and a targeted strategy for neuroprotective intervention in glaucoma.Scheme 1.Schematic illustration of the design and mechanism of an ROS-responsive, CTB-modified nanoparticle (NP-CTB), showing nanoparticle preparation, retinal ganglion cell targeting, injury-responsive drug release, and regulation of TRPV4-associated autophagy under chronic ocular hypertension Schematic illustration of the design and mechanism of an ROS-responsive, CTB-modified nanoparticle (NP-CTB), showing nanoparticle preparation, retinal ganglion cell targeting, injury-responsive drug release, and regulation of TRPV4-associated autophagy under chronic ocular hypertension Methods Animals All animal procedures were approved by the Animal Ethics Committee of Shandong University (Approval No. DWLL-2024–174) and conducted in accordance with relevant institutional guidelines and the NIH Guide for the Care and Use of Laboratory Animals. Six-week-old male Sprague–Dawley rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). COH rat model establishment and intravitreal injection The COH rat model was established following previous procedure [15]. Briefly, the rat was anesthetized by ketamine (25 mg/kg, im) and xylazine (10 mg/kg, im) mixture, and micro-magnetic beads (8uL, BioMag® Superparamagnetic Iron Oxide, Bangs Laboratories, Inc., Fisher, IN, USA) were injected into the anterior chamber of the right eye only once. Following anterior chamber injection of magnetic beads, an external magnet was applied to the eye to distribute the beads evenly and block aqueous outflow at the anterior chamber angle, leading to an increase in IOP. Meanwhile, the contralateral eye (left eye) received a sham injection (0.9% normal saline) conventionally, serving as the sham-operated group. IOP was measured using a handheld digital tonometer (Tonolab, TioLat, Finland), measurements were performed in the morning to prevent potential day and night differences. Our study recorded IOP of both eyes pre-operation (control) and also at 1 and 3 days as well as 1, 2, and 3 weeks after operation. Successful induction of the COH model was defined as an IOP approximately 1.5 times higher than that of control rats. Rats whose IOP returned to baseline were excluded from the study. Before intravitreal injection, the rats were anesthetized following the same procedures described above. We injected Cy5.5 solvent, NPCy5.5, NPCy5.5-CTB, normal saline (NS), NP-CTB (50 μM) or HC-067047 (50 μM) into the vitreous cavity in the same volume (2 μL) slowly to avoid fundus blood vessels using a Hamilton syringe under an ophthalmic surgical microscope. Nanoparticles formulation Preparation of HB A solution of 5 g of 4-(hydroxymethyl) phenylboronic acid pinacol ester in 25.6 mL of anhydrous dichloromethane (DCM) was prepared. To this solution, 3.6 mL of triethylamine was added, and the mixture was cooled to 0 °C. Subsequently, 2.5 mL of methacryloyl chloride was added dropwise slowly. The reaction was stirred at room temperature for 10 h, then filtered. The filtrate was concentrated, diluted with ethyl acetate, and washed three times with saturated brine. The product was concentrated and purified by silica gel column chromatography. Its structure was confirmed by 1H NMR spectroscopy. Synthesis of pDMA DMA was first purified by passing through an alumina column to remove the inhibitor. Subsequently, DMA (2.5 g, 50 equiv.), DCT (203.6 mg, 1 equiv.), and AIBN (16.565 mg, 0.2 equiv.) were dissolved in 1,4-dioxane and transferred into a Schlenk tube for RAFT polymerization. The mixture was subjected to four freeze–pump–thaw cycles and then heated in an oil bath at 75 °C for 5 h. The resulting product was washed three times with a mixed solvent of n-hexane and ethyl acetate (1:1, v/v) and dried under vacuum for 12 h to afford a pale yellow polymer (pDMA). The structure was confirmed by 1H NMR spectroscopy. Synthesis of HB-pDMA HB (200 mg, 50 equiv.), pDMA (67.02 mg, 1 equiv.), and AIBN (0.65 mg, 0.3 equiv.) were dissolved in 1,4-dioxane and transferred into a Schlenk tube for RAFT polymerization. The mixture was subjected to four freeze–pump–thaw cycles and then stirred in an oil bath at 75 °C for 24 h. The resulting mixture was precipitated three times with diethyl ether and dried under vacuum overnight to afford a white solid (HB-pDMA). The structure was confirmed by 1H NMR spectroscopy. Synthesis of HB-pDMA-CTB HB-pDMA (10 mg) and DMTMM (1 mg) were dissolved in 0.5 mL of DMSO. After stirring for 4 h, CTB (10 μL) was added dropwise, and the reaction was allowed to proceed for another 24 h. The mixture was then dialyzed (MWCO: 3.5 kDa) for 5 h and freeze-dried to afford a white solid (HB-pDMA-CTB). The structure was confirmed by 1H NMR spectroscopy. Preparation of NP and NP-CTB nanoparticles For the preparation of NP, HB-pDMA (10 mg) was dissolved in 1 mL of DMSO. HC-067047(1mg/ml, 100 ul) was then added to the solution, and the resulting mixture was injected dropwise into 9 mL of deionized water under vigorous stirring. The mixture was dialyzed using a dialysis bag (MWCO: 3.5 kDa) for 6 h. Following a similar procedure, NP-CTB was synthesized by dissolving HB-pDMA (9 mg) and HB-pDMA-CTB (1 mg) in DMSO. The size and zeta potential of the nanoparticles were measured using a Zetasizer Nano ZS90, and their morphology was characterized by transmission electron microscopy (TEM). Encapsulation efficiency measurement Nanoparticles were prepared following the aforementioned method. The resulting nanoparticle suspension was centrifuged at 10,000 rpm for 30 min, after which the supernatant was collected. The drug concentration in the supernatant was determined by high-performance liquid chromatography (HPLC) and encapsulation efficiency was calculated as follows.\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned} & {\mathrm{Encapsulation}}\;{\mathrm{efficiency}} \\ & \quad = \left( {1 - \frac{{{\mathrm{Drug}}\;{\mathrm{concentration}}\;{\mathrm{in}}\;{\mathrm{supernatant}}}}{{{\mathrm{Total}}\;{\mathrm{drug}}\;{\mathrm{concentration}}}}} \right) \times 100\% \end{aligned}$$\end{document} ROS-responsive release of NP nanoparticles DOX was employed as a model drug to evaluate the ROS-responsive release behavior of the nanoparticles. The nanoparticle suspension was placed in a dialysis bag (MWCO: 3.5 kDa) and incubated at 37 °C in release media containing either 10 mM H₂O₂ or PBS. Samples were taken at predetermined time points (1, 2, 4, 8, 12, 24, and 48 h), and the DOX content was measured to calculate the cumulative release rate. Light/dark transition test The testing apparatus consisted of a dark chamber and a light chamber connected by an open doorway. The test rats were placed in the dark chamber and allowed to move freely within the shuttle box. After the rats were placed in the center of the box, it was allowed to acclimate for 2 min before a 5-min test was conducted. The time the rats spent in the light chamber and the proportion were recorded. After each trial, the apparatus was cleaned with 70% ethanol to eliminate olfactory cues. Investigators were blinded to treatment groups. Visual cliff test The visual cliff test apparatus consists of a clear plexiglass box, separated by a center platform into two regions, the shallow side with a checkered pattern immediately under it, and the deep side with a same checkered pattern under it to create the illusion of depth. Rats were placed onto the center platform, and their choices to step down were recorded. The box and central platform were thoroughly cleaned after each test. Investigators were blinded to treatment groups. Hematoxylin and eosin (H&E) staining H&E staining was completed in accordance with the procedures used previously [15]. In brief, the isolated eyeballs went through the steps of fixation, dehydration, paraffin embedding, sectioning, dewaxing, rehydration, H&E staining, dehydration, and clearing. Subsequently, an optical microscope (Olympus, Japan) was used to image the sections. H&E-stained retinal images were captured at consistent distances from the optic nerve head. Finally, ImageJ software (USA) was used to quantify the number of cells in the GCL. RGCs in the GCL were counted in each image, and retinal length in each image was measured with the multi-segment line tool, allowing calculation of RGC density per unit length. Investigators were blinded to treatment groups. Detection of ROS production and apoptosis Frozen sections of retina tissues in each group (5-μm-thick) were prepared and incubated with DHE (10 mM, MedChemExpress, China) for 30 min in the dark at 37 °C. After staining with DAPI, the sections were observed using a confocal microscope (Nexcope, USA). Subsequently, ROS levels in different groups were observed under the same exposure conditions. OneStep TUNEL Apoptosis Assay Kit (MA0224-2, Meilunbio, China) was implemented to conduct a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) experiment on retinal slices to detect apoptosis. After incubating with DAPI, the slices were observed and images were captured using a fluorescence microscope (Nikon, Japan) or confocal microscope (Nexcope, USA). Investigators were blinded to treatment groups. Whole-mount immunostaining of rats RGCs The eyeballs were fixed in 4% Paraformaldehyde (PFA) at RT for 1 h and then retinas were isolated. The retinas were washed with PBS and treated with blocking solution which contained 0.1% Triton X-100 and 10% goat serum for 1.5 h at RT. Then, the retinas were incubated with primary antibodies against Tuj1 (1:400, 66,375–1-Ig, Proteintech Group) and RBPMS (1:400, 85,086–5-RR, Proteintech Group) overnight at 4 °C. On the following day, the retinas were washed with PBS and incubated with CoraLite 488-conjugated Goat Anti- Mouse (1:200, RGAM002, Proteintech Group) / Rabbit (1:200, SA00013-2, Proteintech Group) IgG(H + L) for 1 h at RT. Finally, the retinas were mounted on microscope slides, and coverslips were placed over them after adding anti-fluorescence quenching mounting medium. Then, Images were acquired using a confocal microscope (Nexcope, USA). Investigators were blinded to treatment groups. Immunofluorescent staining After undergoing dewaxing and rehydration steps, the retinal paraffin sections were sequentially permeabilized with Triton X-100 and blocked with 10% goat serum. Afterward, the sections were subjected to overnight incubation with the primary antibodies against TRPV4 (1:200, TD8624S, Abmart, China), LC3B (1:200, 43566 T, CST, USA), LAMP1 (1:200, 15665 T, CST, USA) and pAMPKThr172 (1:200, TA3423, Abmart, China) at a temperature of 4 ℃. On the following day, the sections were washed with phosphate buffered saline (PBS) and incubated with CoraLite 488-conjugated Goat Anti-Rabbit (1:200, SA00013-2, Proteintech Group. USA) IgG (H + L) or CoraLite® Plus 647-Goat Anti-Mouse Recombinant Secondary Antibody (H + L) (1:200, RGAM005, Proteintech Group, USA) for 1 h at RT. After incubating with DAPI, the anti-fluorescence quenching mounting medium was added dropwise to the tissue sections, and coverslips were placed over them. Images were acquired using a fluorescence microscope (Nikon, Japan) or confocal microscope (Nexcope, USA). Investigators were blinded to treatment groups. Western blotting analyses Western blotting analyses were performed as described previously [15]. The whole fresh retinas were quickly collected and homogenized in ice-cold RIPA lysis buffer (Servicebio, China) supplemented with protease and phosphatase inhibitors (Servicebio, China). The protein sample went through dilution in a loading buffer and was subjected to thermal treatment at 95◦C for a duration of 10 min. The same quantities of protein were subjected to electrophoresis on SDS–polyacrylamide gels, then the protein was transferred to polyvinylidene fluoride membranes (Immobilizer-P, Milipol, Billerica, MA, USA). Following membrane blockage employing 5% bovine serum albumin (BSA) at room temperature (RT) for 1 h, overnight incubation was performed at 4 ℃ with primary antibodies against Bax (1:1000, T40051, Abmart, China), Bcl2 (1:1000, T40056, Abmart, China), Beta-actin (1:50,000, 81,115–1-RR, Proteintech, USA), TRPV4 (1:2000, TD8624S, Abmart, China), Beclin1 (1:6000, 11,306–1-AP, Proteintech, USA), P62 (1:5000, 18,420–1-AP, Proteintech, USA), LC3B (1:1000, 43566 T, CST, USA), and pAMPKThr172 (1:1000, TA3423, Abmart, China). Subsequently, the membranes were washed 3 times with a mixture of TBS solution and Tween 20. Then we incubated the membranes with HRP-conjugated secondary antibody (1:7000, SA00001-2, Proteintech Group, USA) for 1 h at RT. Following the washing process, proteins were identified via dripping the chemiluminescent solution (ECL kit, Servicebio, China) on the PVDF membranes, which were then developed in Tanon 4800 Automatic Chemiluminescence Image Analysis System (Tanon, China) to acquire images. The intensities of the bands were analyzed by ImageJ software (USA). Transmission electron microscopy After the retinas were isolated from the eyeballs, they were immediately immersed in 2.5% glutaraldehyde fixative and fixed overnight at 4 °C. Retinas were then post-fixed in 1% osmium tetroxide at 4 °C for 1.5 h, followed by conventional graded ethanol dehydration, resin infiltration, embedding, and polymerization. Ultrathin sections with a thickness of 50–70 nm were cut using an ultramicrotome. The sections were stained sequentially with saturated aqueous uranyl acetate for 30 min and lead citrate for 30 min. The samples were observed with Talos F200C transmission electron microscope (Thermo Fisher Scientific, USA). The search for autophagosomes and autolysosomes was conducted in accordance with “Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)” [37]. Investigators were blinded to treatment groups. Pharmacological treatment Rats were injected intraperitoneally with hydroxychloroquine (HCQ, 10 mg/kg, MedChemExpress) on the 5th or the 12th day of COH, 3-methyladenine (3-MA, 25 mg/kg, MedChemExpress) on the 5th or the 12th day of COH, rapamycin (5 mg/kg, MedChemExpress) on the 12th day of COH, compound C (5 mg/kg, MedChemExpress) daily from day 8 to day 13 of COH. Control rats were injected with the same volume of NS in the same way. Statistical analyses The data are shown as the mean ± SD or as direct values. All the statistical analyses were performed using Prism statistical software (GraphPad) version 8.0.2 (USA). Differences between two groups were evaluated using an unpaired t-test, while comparisons across multiple groups were analyzed via one-way analysis of variance (ANOVA). A probability (P) value of < 0.05 was deemed statistically significant. Results RGC apoptosis and TRPV4 activation were induced in COH models We successfully established a COH rat model. The schematic illustration of the rat COH model is shown in Fig. 1A. Before modeling, non-significant difference was found in IOP between the two eyes, and the IOP of the sham-operated (control) group was 7.85 ± 0.85 mmHg. After modeling, IOP of the right eye began to increase on day 3 and remained at a high level of approximately 22.58 ± 3.17 mmHg from days 7 to 21 (Fig. 1B).Fig. 1Progressive RGC and optic nerve degeneration in the COH rat model, accompanied by TRPV4 upregulation and retinal inflammatory activation. (A) Schematic illustration of the COH establishment. (B) Time course of IOP changes in control eyes and COH eyes following model induction (n = 6). (C–D) Representative HE–stained retinal sections from control and COH eyes at different time points after model induction, with quantification of RGC numbers. Scale bar, 50 μm. (E–F) Representative TUNEL-stained retinal sections from COH eyes at different time points after model induction, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (G–H) Representative immunofluorescence images showing TRPV4 expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of TRPV4 expression levels. TRPV4 is shown in red, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (I–J) Representative immunofluorescence images showing GFAP expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of GFAP-positive area fraction%. GFAP is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (K–L) Representative immunofluorescence images showing IBA1 expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of the density of IBA1-positive cells. IBA1 is shown in red, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (M–Q) Western blotting analysis of Bax, Bcl2, TRPV4, GFAP and IBA1 expression in retinal tissues from control and COH eyes at different time points after model induction, with quantification of the Bax/Bcl2 ration, protein levels of TRPV4, GFAP and IBA1. (R–S) Representative immunofluorescence images showing the nerve fibers marked by Tuj1 at the optic nerve head in retinal sections from control and COH eyes at different time points after model induction, with quantification of the width of nerve fibers. Tuj1 is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using unpaired Student’s t-test (B) or one-way ANOVA (D, F, H, J, L, N, O, P, Q, S). Data are presented as mean ± SD. In (B), ***P < 0.001 vs. sham-operated eyes at the same time point, and ##P < 0.01, ###P < 0.001 vs. control eyes. In (D, F, H, J, L, N, O, P, Q, S), *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant Progressive RGC and optic nerve degeneration in the COH rat model, accompanied by TRPV4 upregulation and retinal inflammatory activation. (A) Schematic illustration of the COH establishment. (B) Time course of IOP changes in control eyes and COH eyes following model induction (n = 6). (C–D) Representative HE–stained retinal sections from control and COH eyes at different time points after model induction, with quantification of RGC numbers. Scale bar, 50 μm. (E–F) Representative TUNEL-stained retinal sections from COH eyes at different time points after model induction, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (G–H) Representative immunofluorescence images showing TRPV4 expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of TRPV4 expression levels. TRPV4 is shown in red, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (I–J) Representative immunofluorescence images showing GFAP expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of GFAP-positive area fraction%. GFAP is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (K–L) Representative immunofluorescence images showing IBA1 expression in retinal sections from control and COH eyes at different time points after model induction, with quantification of the density of IBA1-positive cells. IBA1 is shown in red, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (M–Q) Western blotting analysis of Bax, Bcl2, TRPV4, GFAP and IBA1 expression in retinal tissues from control and COH eyes at different time points after model induction, with quantification of the Bax/Bcl2 ration, protein levels of TRPV4, GFAP and IBA1. (R–S) Representative immunofluorescence images showing the nerve fibers marked by Tuj1 at the optic nerve head in retinal sections from control and COH eyes at different time points after model induction, with quantification of the width of nerve fibers. Tuj1 is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using unpaired Student’s t-test (B) or one-way ANOVA (D, F, H, J, L, N, O, P, Q, S). Data are presented as mean ± SD. In (B), ***P < 0.001 vs. sham-operated eyes at the same time point, and ##P < 0.01, ###P < 0.001 vs. control eyes. In (D, F, H, J, L, N, O, P, Q, S), *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant The retinas from the COH and control eyes were harvested, and hematoxylin and eosin (HE) staining results revealed that, compared with the control group, the retinal structure of the COH group gradually became irregular, with loose and disordered distribution of each layer and varying degrees of edema, and RGC number gradually decreased as the disease progressed (Fig. 1C, D). Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining revealed that TUNEL-positive cells in the GCL significantly increased on day 7 of COH and further increased on day 14 (Fig. 1E, F), indicating progressively aggravated RGC apoptosis. Consistently, Western blotting revealed that, compared with the control group, the Bcl-2–associated X (Bax) to B-cell lymphoma 2 (Bcl2) ratio in the retina was significantly increased on days 7 and 14 of COH, with a peak observed on day 7 (Fig. 1M, N). We further examined TRPV4 expression changes during COH progression. Immunofluorescence results identified that, compared with the control group, TRPV4 expression in the retina presented no obvious change on day 7 of COH; however, it became significantly increased on day 14, predominantly within GCL (Fig. 1G, H). Western blotting results were consistent with this observation. Compared with the control group, retinal TRPV4 protein levels revealed a non-significant difference on day 7 of COH; however, they were markedly increased on day 14 (Fig. 1M, O). We also assessed inflammatory infiltration in the retina under COH. Immunofluorescence results showed that by day 7 post-COH induction, both Müller cells and microglia were markedly activated, and this inflammatory state persisted through day 14 of the COH course (Fig. 1I–L). Western blot analysis similarly revealed that GFAP and IBA1 expression was elevated by day 7 and remained high until day 14 (Fig. 1M, P, Q). Finally, we investigated the neurodegenerative changes in the optic nerve induced by COH. We performed immunostaining of the neural fiber marker βIII-tubulin (Tuj1) on the nerve fibers at the optic nerve head. The results showed that by day 7 after the induction of COH, the width of the nerve fibers was significantly reduced (Fig. 1R, S). These results indicate that under COH, structural and functional damage to RGCs and optic nerve progressively worsened, accompanied by a significant TRPV4 upregulation by day 14. Preparation and characterization of nanoparticles The synthesis and characterization of NP-CTB are summarized in Fig. 2. To improve the solubility of the TRPV4 antagonist and enhance its accumulation in retinal ganglion cells, we designed the ROS-responsive polymer HB-pDMA. This polymer self-assembles into micelles that dissociate under high ROS conditions, thereby releasing the encapsulated drug. NP-CTB nanoparticles were formed through the copolymerization of hydrophilic DMA and hydrophobic HB (Fig. 2A and Figure S1-S5, Supporting Information). Their encapsulation efficiency was determined to be 89.28% via high-performance liquid chromatography (HPLC) (Figure S6). Our study on retinal sections revealed that COH rats exhibited substantial ROS accumulation compared to normal rats, providing physiological conditions for the ROS response to nanoparticles (Fig. 2B, C). Dynamic light scattering (DLS) measurements using a Malvern particle size analyzer revealed that NP-CTB had an average hydrodynamic diameter of 164 nm and a polydispersity index (PDI) of 0.097 (Fig. 2D). As shown by transmission electron microscopy (TEM), the nanoparticles exhibited a uniform spherical morphology (Fig. 2E). And NP-CTB had a zeta potential of -2.41 mV (Fig. 2F).Fig. 2Preparation and characterization of NP-CTB nanoparticles. (A) Schematic illustration of NP-CTB synthesis. (B–C) Representative immunofluorescence images showing production of ROS in retinal sections from normal rats or COH rats, with quantification of DHE fluorescence intensity in the GCL. Scale bar, 50 μm. DHE signals are shown in red, and nuclei are counterstained with DAPI (blue). (D) Representative size of NP-CTB nanoparticles. (E) Representative TEM images of NP-CTB nanoparticles. Scale bar, 200 nm. (F) Representative zeta potential of NP-CTB nanoparticles. Representative size (G) and TEM images (H) of NP-CTB after H2O2 treatment. Scale bar, 200 nm. (I) ROS-responsive release of NP-CTB in H2O2. Statistical analysis was performed using unpaired Student’s t-test (C) and data are presented as the mean ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Preparation and characterization of NP-CTB nanoparticles. (A) Schematic illustration of NP-CTB synthesis. (B–C) Representative immunofluorescence images showing production of ROS in retinal sections from normal rats or COH rats, with quantification of DHE fluorescence intensity in the GCL. Scale bar, 50 μm. DHE signals are shown in red, and nuclei are counterstained with DAPI (blue). (D) Representative size of NP-CTB nanoparticles. (E) Representative TEM images of NP-CTB nanoparticles. Scale bar, 200 nm. (F) Representative zeta potential of NP-CTB nanoparticles. Representative size (G) and TEM images (H) of NP-CTB after H2O2 treatment. Scale bar, 200 nm. (I) ROS-responsive release of NP-CTB in H2O2. Statistical analysis was performed using unpaired Student’s t-test (C) and data are presented as the mean ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 To verify the ROS-responsive behavior of NP-CTB, the nanoparticles were treated with 10 mM H₂O₂. Within two hours, the nanoparticles were disrupted, as evidenced by a marked increase in particle size to over 1 μm (Fig. 2G). Corresponding TEM images confirmed significant dissociation, resulting in irregular aggregates (Fig. 2H). For drug release studies, DOX-loaded nanoparticles (NP-DOX) were incubated at 37 °C in PBS and 0.1 mM、1 mM、5 mM、10 mM H₂O₂ solution. The accumulative release of DOX was measured at various time points (Fig. 2I). The accumulative release of NP-CTB at 48 h was ~ 40% in the presence of 0.1 mM H₂O₂, ~ 60% at 1 mM H₂O₂, and exceeded 80% at both 5 mM and 10 mM H₂O₂. These results demonstrate that NP-CTB nanoparticles possess high ROS responsiveness. They are capable of rapidly disassembling under elevated ROS levels in vivo, thereby releasing the encapsulated antagonist to exert its therapeutic effect. RGC-targeting delivery and ROS-responsive controlled nanoparticle release in COH models We first verified the NP-CTB targeting capability toward RGCs. To achieve this, we conjugated the fluorescent dye Cy5.5 with NP or NP-CTB to generate NPCy5.5 and NPCy5.5-CTB, respectively. Rats were randomly assigned into three groups and intravitreally injected with equimolar free Cy5.5 solvent, NPCy5.5, or NPCy5.5-CTB. Retinas were collected on days 1, 3, 7, and 14 post-injection for whole-mount preparation to assess Cy5.5 fluorescence distribution within RGCs (Fig. 3A). The results revealed that on day 1 after injection, Cy5.5 fluorescence in the NPCy5.5-CTB group exhibited pronounced colocalization with the Tuj1, indicating rapid nanoparticle entry into RGCs. Moreover, Cy5.5 fluorescence remained colocalized with Tuj1 on day 14 post-injection (Fig. 3B), demonstrating prolonged retention of NPCy5.5-CTB in RGCs. Compared with NPCy5.5 and free Cy5.5 solvent groups, the NPCy5.5-CTB group exhibited markedly stronger Cy5.5 fluorescence in the optic nerve axonal layer, and a significantly larger colocalization area with Tuj1 on days 1 and 3 post-injection (Fig. 3C–E), further confirming that CTB modification markedly enhanced the specificity and uptake efficiency of the nanoparticles targeting RGCs.Fig. 3NP-CTB exhibits efficient RGC targeting and selective drug release under COH. (A) Schematic illustration used to evaluate the effect of CTB modification on the RGC targeting of nanoparticles. (B) Representative fluorescence images of retinal flat mounts showing colocalization of Cy5.5-labeled nanoparticles with RGCs at different time points after intravitreal injection (IVI). RGCs are labeled with Tuj1 (green), and Cy5.5-labeled nanoparticles are shown in magenta. Scale bar, 50 μm. (C–E) Representative fluorescence images showing Cy5.5 fluorescence in the optic nerve fiber layer and its colocalization with RGCs at days 1 and 3 after intravitreal injection in the free Cy5.5 solvent, NPCy5.5, and NPCy5.5-CTB groups, with quantification of Cy5.5 fluorescence intensity and colocalization area with Tuj1-positive cells. Scale bar, 50 μm. (F–H) Representative immunofluorescence images showing TRPV4 expression in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on day 7 post-COH induction, compared with NS-treated controls given in the same manner, with quantification of TRPV4 fluorescence intensity in the GCL. Scale bar, 50 μm. TRPV4 is shown in red, and nuclei are counterstained with DAPI (blue). (I–L) Western blotting analysis of TRPV4 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of TRPV4 protein levels. (M–O) Representative TUNEL-stained retinal sections images in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA (D, E) or unpaired Student’s t-test (G, H, J, K, L, N, O) and data are presented as mean ± SD (n = 3–5). *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant NP-CTB exhibits efficient RGC targeting and selective drug release under COH. (A) Schematic illustration used to evaluate the effect of CTB modification on the RGC targeting of nanoparticles. (B) Representative fluorescence images of retinal flat mounts showing colocalization of Cy5.5-labeled nanoparticles with RGCs at different time points after intravitreal injection (IVI). RGCs are labeled with Tuj1 (green), and Cy5.5-labeled nanoparticles are shown in magenta. Scale bar, 50 μm. (C–E) Representative fluorescence images showing Cy5.5 fluorescence in the optic nerve fiber layer and its colocalization with RGCs at days 1 and 3 after intravitreal injection in the free Cy5.5 solvent, NPCy5.5, and NPCy5.5-CTB groups, with quantification of Cy5.5 fluorescence intensity and colocalization area with Tuj1-positive cells. Scale bar, 50 μm. (F–H) Representative immunofluorescence images showing TRPV4 expression in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on day 7 post-COH induction, compared with NS-treated controls given in the same manner, with quantification of TRPV4 fluorescence intensity in the GCL. Scale bar, 50 μm. TRPV4 is shown in red, and nuclei are counterstained with DAPI (blue). (I–L) Western blotting analysis of TRPV4 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of TRPV4 protein levels. (M–O) Representative TUNEL-stained retinal sections images in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA (D, E) or unpaired Student’s t-test (G, H, J, K, L, N, O) and data are presented as mean ± SD (n = 3–5). *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant We subsequently assessed the pathological environment-specific drug release capacity of NP-CTB. Considering that RGC damage and optic nerve degeneration occur as early as day 7 after COH induction, in addition to the 48-h pretreatment prior to COH modeling, we also administered the treatment on the 7th day of COH and subsequently assessed the relevant parameters on day 14. Immunofluorescence analysis showed that 16 days after intravitreal injection of NP-CTB, TRPV4 expression in the retina under normal physiological conditions remained unchanged (Figure S7). However, under the pathological conditions of COH, NP-CTB was able to significantly reduce TRPV4 expression in the GCL regardless of whether it was administered as a pretreatment or on day 7 post-COH induction, without affecting other retinal layers (Fig. 3F, G, H). Western blotting further showed that intravitreal injection of NP-CTB not only prior to COH induction reduced TRPV4 expression in the rat retina on both day 7 and day 14 of the COH course, but also that intravitreal injection on day 7 post-COH induction effectively decreased TRPV4 expression in the retina on day 14 (Fig. 3I, J, K, L). Finally, TUNEL staining revealed that NP-CTB significantly reduced the number of apoptotic cells in the GCL regardless of whether it was administered as a pretreatment or on day 7 post-COH induction, without affecting other retinal layers (Fig. 3M, N, O). To assess whether NP-CTB exerts off-target effects, we assessed a series of parameters. The results showed that intravitreal injection of NP-CTB did not affect IOP, retinal thickness or RGC density in healthy rats (Figure S8A–D), nor did it impact quiescent Müller cells or microglia (Figure S8E–H). In conclusion, we demonstrated that NP-CTB efficiently targeted RGCs and released HC-067047 within the COH injury microenvironment, thereby achieving specific protection of RGCs. Nanoparticles protected RGCs from COH injury better than free HC-067047 Firstly, we assessed IOP under two separate treatment schedules: one with drug administration 2 days prior to COH induction, and the other with administration on the 7th day of COH. Under both administration regimens, there were no significant differences in IOP among the COH groups receiving intravitreal injections of NS, HC-067047, or NP-CTB at any of the measured time points, and all groups met the criteria for successful establishment of the COH model (Fig. 4A, B).Fig. 4Comparative effects of free HC-067047 and NP-CTB on RGC survival during COH. (A–B) Time course of IOP changes in control eyes and COH eyes receiving intravitreal injections of NS, HC-067047, or NP-CTB under both administration regimens (n = 10). (C) Schematic illustration of the light–dark transition test. (D–E) Quantitative analysis of white box occupancy time ratio in the light–dark transition test performed in control rats and in 14 days with COH rats treated with NP-CTB either as a pretreatment or on day 7 post-COH induction, compared with NS or HC-067047-treated groups given in the same manner. (F) Schematic illustration of the visual cliff test. (G–H) Visual cliff performance, from control rats and COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner. Data showed the number of shallow/deep side choosers. (I–K) Representative HE stained images from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner, showing RGCs in the central, middle, and peripheral regions, with quantification of RGC density in each region. Scale bar, 50 μm. (L–O) Representative fluorescence images of retinal flat mounts from control rats and COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner, showing RGCs in the central, middle, and peripheral regions, with quantification of RGC density in each region. RGCs are labeled with RBPMS (yellow). Scale bar, 50 μm. (P–S) Western blotting analysis of Bax and Bcl2 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated controls given in the same manner, with quantification of the Bax/Bcl2 ratio. (T–W) Representative immunofluorescence images showing the nerve fibers marked by Tuj1 at the optic nerve head in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated controls given in the same manner, with quantification of the width of nerve fibers. Tuj1 is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA and data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant Comparative effects of free HC-067047 and NP-CTB on RGC survival during COH. (A–B) Time course of IOP changes in control eyes and COH eyes receiving intravitreal injections of NS, HC-067047, or NP-CTB under both administration regimens (n = 10). (C) Schematic illustration of the light–dark transition test. (D–E) Quantitative analysis of white box occupancy time ratio in the light–dark transition test performed in control rats and in 14 days with COH rats treated with NP-CTB either as a pretreatment or on day 7 post-COH induction, compared with NS or HC-067047-treated groups given in the same manner. (F) Schematic illustration of the visual cliff test. (G–H) Visual cliff performance, from control rats and COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner. Data showed the number of shallow/deep side choosers. (I–K) Representative HE stained images from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner, showing RGCs in the central, middle, and peripheral regions, with quantification of RGC density in each region. Scale bar, 50 μm. (L–O) Representative fluorescence images of retinal flat mounts from control rats and COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated groups given in the same manner, showing RGCs in the central, middle, and peripheral regions, with quantification of RGC density in each region. RGCs are labeled with RBPMS (yellow). Scale bar, 50 μm. (P–S) Western blotting analysis of Bax and Bcl2 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated controls given in the same manner, with quantification of the Bax/Bcl2 ratio. (T–W) Representative immunofluorescence images showing the nerve fibers marked by Tuj1 at the optic nerve head in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS or HC-067047-treated controls given in the same manner, with quantification of the width of nerve fibers. Tuj1 is shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA and data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant Subsequently, we evaluated the neuroprotective effects of NP-CTB on RGCs under COH conditions using multiple assays and compared these effects with intravitreal administration of free HC-067047 at the same concentration and volume. Two treatment schedules were employed: one with intravitreal injection 48 h prior to COH induction, and the other on the 7th day of COH. The protective efficacy of NP-CTB on RGCs was assessed under both treatment schedules. Visual function was evaluated using the light/dark transition test and the visual cliff test. Light/dark transition test relied on the natural preference of rodents for dark environments, and a higher white box occupancy time ratio indicated a poorer ability to distinguish between light and dark conditions (Fig. 4C). The results revealed that healthy rats maintained a stable white box occupancy time ratio of approximately 18%, whereas COH rats exhibited a markedly increased ratio, indicating impaired visual function. Compared with the NS group, administration of HC-067047 or NP-CTB prior to COH induction significantly reduced the white box occupancy time ratio, with NP-CTB producing a more pronounced effect (Fig. 4D). In contrast, when administered on the 7th day of COH, HC-067047 failed to reduce the white box occupancy time ratio, whereas NP-CTB still induced a significant reduction (Fig. 4E). In addition, we employed the visual cliff test to assess depth perception in rats. This test is based on the innate tendency of rodents to avoid the deep side of the cliff and prefer the shallow side. Rats were placed on a central platform between the deep and shallow sides, and their choice of which side to move toward was recorded (Fig. 4F). In the normal rat group, all 12 rats chose the shallow side. In COH rats with pretreatment, only 3 of 12 rats in the NS group chose the shallow side, indicating poor performance, compared with 6 of 12 in the HC-067047 group and 10 of 12 in the NP-CTB group (Fig. 4G). In the experiment with drug administration on the 7th day of COH, 3 of 12 rats in the HC-067047 group chose the shallow side, whereas 9 of 12 rats in the NP-CTB group did so (Fig. 4H). Next, we assessed the neuroprotective effects of NP-CTB on RGCs using multiple experimental approaches and compared its efficacy with that of free HC-067047 at the same concentration. HE staining revealed that, under the pretreatment condition, HC-067047 significantly increased RGC density in the middle and peripheral regions of the retina at day 14 compared with the NS group. In contrast, NP-CTB not only provided more pronounced protection in the middle and peripheral regions but also effectively mitigated the reduction of RGC density in the central region (Fig. 4I, J). Under the condition of drug administration on the 7th day of COH, HC-067047 showed no protective effect on RGCs in any retinal region at day 14, whereas NP-CTB remained able to effectively preserve RGCs in the central and middle regions (Fig. 4I, K). Consistently, RBPMS immunofluorescence staining of retinal whole-mounts revealed similar findings. When administered prior to COH induction, HC-067047 effectively mitigated the reduction of RGC density in the middle and peripheral retinal regions, whereas NP-CTB preserved RGCs across the entire retina (Fig. 4L, M). In contrast, when administered on the 7th day of COH, HC-067047 showed no protective effect in any retinal region, while NP-CTB continued to effectively maintain RGC density in the central and middle regions (Fig. 4N, O). Western blot analysis was also employed to evaluate the neuroprotective effects of NP-CTB. When administered prior to COH induction, both HC-067047 and NP-CTB effectively reduced the Bax/Bcl2 ratio in the retina on the 7th day and 14th day of COH, with NP-CTB exhibiting superior efficacy compared with HC-067047. However, when administered on the 7th day of COH, HC-067047 was no longer able to reduce the Bax/Bcl2 ratio, whereas NP-CTB remained able to significantly suppress the elevation of Bax/Bcl2 in the retina at day 14 (Fig. 4P–S). Finally, we compared the protective effects of HC-067047 and NP-CTB on optic nerve degeneration. When administered 48 h prior to COH induction, both HC-067047 and NP-CTB effectively maintained fiber width, with NP-CTB showing superior performance (Fig. 4T, U); and when administered on 7th day of COH, HC-067047 could no longer preserve fiber width, whereas NP-CTB still provided effective protection (Fig. 4V, W). Taken together, these findings indicated that, compared with the free TRPV4 antagonist HC-067047, NP-CTB provided superior protection against COH-induced RGC damage. Decline in autophagic flux played a key role in COH-induced RGC apoptosis We first used TEM to examine autophagosomes (APs) and autolysosomes (ALs) in GCL at different time points of COH and quantitatively analyzed their densities. The results revealed that, compared with the control group, AP and AL numbers in the GCL significantly increased on day 7 of COH. However, compared with day 7, AP and AL numbers in the GCL were markedly reduced on day 14 of COH (Fig. 5A–C). We then performed double immunofluorescence staining for microtubule-associated protein 1 light chain 3 beta (LC3B) and the lysosomal marker lysosome-associated membrane protein 1 (LAMP1) in retinal sections. The results revealed that the LC3B/LAMP1 double-positive cell proportion in GCL increased on day 7 of COH and decreased on day 14 (Fig. 5D, E), consistent with the changes in AP and AL numbers observed using TEM.Fig. 5Dynamic changes in autophagic flux during COH and their association with RGC survival. (A–C) Representative TEM images showing APs and ALs in the GCL and quantitative analysis of AP and AL densities at different time points following COH induction. The white arrows indicate AP and the red arrows indicate the electron-dense in AL. Scale bar, 1 μm. (D–E) Representative double immunofluorescence images showing LC3B (green) and LAMP1 (red) in retinal sections from control rats and COH rats at days 7 and 14, with quantification of LC3B/LAMP1 double-positive cells. Scale bar, 50 μm. (F–G) Western blotting analysis and quantification of Beclin1 in retinal tissues from control rats and COH rats at days 7 and 14. (H–J) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from control rats and COH rats at day 7 with or without HCQ treatment. (K–L) Representative TUNEL images of retinal sections from COH rats, treated with NS, HCQ, or 3-MA and analyzed at day 7, with quantification of relative TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (M–N) Western blotting analysis and quantification of Bax/Bcl2 in retinal tissues from COH rats treated with or without HCQ and analyzed at day 7. (O–P) Western blotting analysis and quantification of LC3-II and Bax/Bcl2 in retinal tissues from COH rats treated with or without 3-MA and analyzed at day 7. (Q–S) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from COH rats at day 7, and COH rats at day 14 with or without HCQ treatment. (T–U) Representative TUNEL images of retinal sections from COH rats, treated with NS, rapamycin, or HCQ and analyzed at day 14, with quantification of relative TUNEL-positive cells in the GCL. Scale bar, 50 μm. (V–W) Western blotting analysis and quantification of Bax/Bcl2 in retinal tissues from COH rats treated with or without HCQ and analyzed at day 14. (X–Y) Western blotting analysis and quantification of LC3-II and Bax/Bcl2 in retinal tissues from COH rats treated with or without rapamycin and analyzed at day 14. Statistical analysis was performed using one-way ANOVA (B, C, E, G, I, J, L, U) or unpaired Student’s t-test (N, P, W, Y) and data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 Dynamic changes in autophagic flux during COH and their association with RGC survival. (A–C) Representative TEM images showing APs and ALs in the GCL and quantitative analysis of AP and AL densities at different time points following COH induction. The white arrows indicate AP and the red arrows indicate the electron-dense in AL. Scale bar, 1 μm. (D–E) Representative double immunofluorescence images showing LC3B (green) and LAMP1 (red) in retinal sections from control rats and COH rats at days 7 and 14, with quantification of LC3B/LAMP1 double-positive cells. Scale bar, 50 μm. (F–G) Western blotting analysis and quantification of Beclin1 in retinal tissues from control rats and COH rats at days 7 and 14. (H–J) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from control rats and COH rats at day 7 with or without HCQ treatment. (K–L) Representative TUNEL images of retinal sections from COH rats, treated with NS, HCQ, or 3-MA and analyzed at day 7, with quantification of relative TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (M–N) Western blotting analysis and quantification of Bax/Bcl2 in retinal tissues from COH rats treated with or without HCQ and analyzed at day 7. (O–P) Western blotting analysis and quantification of LC3-II and Bax/Bcl2 in retinal tissues from COH rats treated with or without 3-MA and analyzed at day 7. (Q–S) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from COH rats at day 7, and COH rats at day 14 with or without HCQ treatment. (T–U) Representative TUNEL images of retinal sections from COH rats, treated with NS, rapamycin, or HCQ and analyzed at day 14, with quantification of relative TUNEL-positive cells in the GCL. Scale bar, 50 μm. (V–W) Western blotting analysis and quantification of Bax/Bcl2 in retinal tissues from COH rats treated with or without HCQ and analyzed at day 14. (X–Y) Western blotting analysis and quantification of LC3-II and Bax/Bcl2 in retinal tissues from COH rats treated with or without rapamycin and analyzed at day 14. Statistical analysis was performed using one-way ANOVA (B, C, E, G, I, J, L, U) or unpaired Student’s t-test (N, P, W, Y) and data are presented as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 We further examined the autophagy-related protein expression by Western blotting. Compared with the control group, retinal Beclin1 and LC3-II levels were significantly enhanced on day 7 of COH. However, p62 expression was decreased, indicating an enhancement in autophagic flux at this stage. To determine whether the observed increase in autophagic flux on day 7 resulted from autophagy activation rather than impaired autophagic degradation, we treated COH rats with HCQ, an inhibitor that blocks autophagosome–lysosome fusion. The results revealed that p62 protein levels further increased after HCQ treatment, supporting the notion that elevated IOP activates autophagy in RGCs (Fig. 5F–J). To assess the specific effect of the pronounced alteration in autophagic flux observed on day 7 of COH on RGC survival, we performed pharmacological interventions targeting the upstream initiation and downstream degradation stages of the autophagic pathway and subsequently assessed the extent of RGC apoptosis. On day 5, the three groups of rats were intraperitoneally injected with NS, HCQ, or the autophagy inhibitor 3-MA. The results revealed that, compared with the NS group, HCQ or 3-MA treatment further increased TUNEL-positive cell number in GCL on day 7 of COH (Fig. 5K, L). And Western blotting results showed that HCQ or 3-MA treatment increased the Bax/Bcl2 ratio on day 7 of COH (Fig. 5M–P). Compared with day 7 of COH, Beclin1, LC3-II, and p62 levels were significantly reduced on day 14. After HCQ administration on day 12, p62 and LC3-II levels markedly increased on day 14, suggesting that the degradation phase of autophagy was not persistently blocked (Fig. 5F, G, and Q–S). Combined with the evident reduction in AP and AL numbers under TEM on day 14 and decreased LC3B/LAMP1 colocalization in retinal sections, we concluded that the decline in autophagic flux on day 14 was primarily attributed to reduced autophagic activity. Similarly, rats on day 12 of COH were divided into three groups and intraperitoneally injected with NS, HCQ, or autophagy activator rapamycin. The results indicated that, compared with the NS group, HCQ treatment further increased the TUNEL-positive cell number in the GCL on day 14 of COH, whereas rapamycin treatment reduced the TUNEL-positive cell number in the GCL (Fig. 5T, U). Western blotting results showed that the Bax/Bcl2 ratio exhibited a similar trend (Fig. 5V–Y). Taken together, in the COH model, autophagic flux in RGCs increased and remained relatively active on day 7, and this enhancement of autophagy helped mitigate COH-induced RGC damage; however, by day 14, autophagic flux markedly declined. Notably, pharmacological reactivation of autophagy after day 7 also effectively reduced COH-induced RGC injury, indicating that maintaining an appropriate level of autophagic flux played a crucial protective role in enabling RGCs to resist COH-related damage. Nanoparticles protected RGCs by promoting autophagic flux in COH We further evaluated the regulatory effects of NP-CTB on RGC autophagy in COH rats. We first used TEM to assess the effect of NP-CTB on autophagic morphological changes in RGCs during COH. The results revealed that, when the drug was administered via intravitreal injection 48 h prior to COH induction, compared with the NS group, the NP-CTB group exhibited a significant reduction in autophagosome number in RGCs on day 7; however, no obvious change was observed in the number of ALs; on day 14, APs and ALs markedly increased (Fig. 6A, B, C); when the drug was administered via intravitreal injection on day 7 post-COH induction, compared with the NS group, NP-CTB group exhibited higher densities of autophagosomes and autolysosomes in RGCs (Fig. 6A, D).Fig. 6Effects of NP-CTB on autophagic flux in RGCs during the COH progression. (A–D) Representative TEM images showing APs and ALs in the GCL from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of analysis of AP and AL densities at different time points after COH induction. The white arrows indicate AP and the red arrows indicate the electron-dense in AL. Scale bar, 1 μm. (E–H) Representative double immunofluorescence images showing LC3B (green) and LAMP1 (red) in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of LC3B/LAMP1 double-positive cells in the GCL. Scale bar, 50 μm. (I–K) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 7 and COH rats pretreated with NP-CTB alone or in combination with HCQ. (L–N) Western blotting analysis and quantification of Beclin1 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of Beclin1 expression. (O–Q) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 14 and COH rats pretreated with NP-CTB alone or in combination with HCQ. (R–T) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 14 and COH rats treated with NP-CTB on the 7th day of COH alone or in combination with HCQ. Statistical analysis was performed using unpaired Student’s t-test (B, C, D, F, H) or one-way ANOVA (J, K, M, N, P, Q, S, T). Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant Effects of NP-CTB on autophagic flux in RGCs during the COH progression. (A–D) Representative TEM images showing APs and ALs in the GCL from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of analysis of AP and AL densities at different time points after COH induction. The white arrows indicate AP and the red arrows indicate the electron-dense in AL. Scale bar, 1 μm. (E–H) Representative double immunofluorescence images showing LC3B (green) and LAMP1 (red) in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of LC3B/LAMP1 double-positive cells in the GCL. Scale bar, 50 μm. (I–K) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 7 and COH rats pretreated with NP-CTB alone or in combination with HCQ. (L–N) Western blotting analysis and quantification of Beclin1 in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of Beclin1 expression. (O–Q) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 14 and COH rats pretreated with NP-CTB alone or in combination with HCQ. (R–T) Western blotting analysis and quantification of LC3-II and p62 in retinal tissues from NS-treated COH rats analyzed at day 14 and COH rats treated with NP-CTB on the 7th day of COH alone or in combination with HCQ. Statistical analysis was performed using unpaired Student’s t-test (B, C, D, F, H) or one-way ANOVA (J, K, M, N, P, Q, S, T). Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001; ns, not significant We further investigated the effects of NP-CTB on autophagic flux in RGCs on day 14. Double immunofluorescence staining revealed that, whether NP-CTB was administered via intravitreal injection 48 h prior to COH induction or on day 7 post-induction, the number of LC3B–LAMP1 double-positive cells in the GCL was increased on day 14 of COH compared with the NS-injected group (Fig. 6E, F, G, H), indicating a restoration of impaired autophagic flux. We then analyzed the changes in autophagy-related protein expression using western blotting. When NP-CTB was administered prior to COH induction, p62 expression was further reduced on day 7 of COH. Moreover, simultaneous treatment with HCQ led to increased levels of LC3-II and p62 (Fig. 6I, J, K), indicating that pretreatment with NP-CTB enhanced autophagic flux in RGCs on day 7 by promoting autophagic degradation, thereby exerting a protective effect on RGCs. At day 14 post-COH induction, pretreatment with NP-CTB increased the expression of Beclin1, LC3-II, and p62, and co-administration of HCQ further elevated p62 levels (Fig. 6L, M, O, P, Q), indicating that NP-CTB pretreatment enhanced autophagy activation in RGCs at this time point. When NP-CTB was administered on day 7 after COH induction, it did not markedly affect Beclin1 expression (Fig. 6L, N) but significantly reduced LC3-II and p62 levels. Co-treatment with HCQ restored p62 expression (Fig. 6R, S, T), further indicating that NP-CTB promoted autophagic flux in RGCs at this time point of the COH course. Taken together, these results suggest that NP-CTB can enhance both upstream autophagy activation and downstream degradation in RGCs, thereby exerting a protective effect on these cells. Nanoparticles might activate autophagy and protect RGCs by enhancing AMPK phosphorylation Phosphorylation of AMP-activated protein kinase (AMPK) at Thr172 is required for autophagy activation and is regulated by calcium channels [38]. However, it remains unclear whether pAMPKThr172 in RGCs of the COH model was affected by TRPV4 activation, thereby interfering with its autophagy-regulating function. We further investigated the changes in pAMPKThr172 during COH and its relationship with the effects of nanoparticle treatment. First, immunofluorescence staining revealed that compared with the control group, pAMPKThr172 fluorescence intensity in the GCL was markedly increased on day 7 of COH; however, it significantly decreased on day 14 (Fig. 7A, B). Western blotting results were consistent with these findings (Fig. 7C, D), and the temporal pattern paralleled the previously described changes in autophagic flux. Intravitreal injection of the nanoparticles, whether administered 48 h prior to COH induction or on day 7 post-induction, significantly increased both the fluorescence intensity of pAMPK in the GCL (Fig. 7E–G) and the retinal pAMPK expression on day 14 of COH (Fig. 7H–J), suggesting that the COH-induced, TRPV4-associated pAMPKThr172 downregulation could be partially reversed by the nanoparticles. Furthermore, while administering the nanoparticles, we intraperitoneally injected the AMPK inhibitor compound C daily from days 8 to 13 of COH and collected tissues on day 14. The results exhibited that compound C suppressed nanoparticle-induced pAMPKThr172 restoration, weakened the nanoparticle-mediated enhancement of autophagic activity in RGCs on day 14 of COH, and led to an increased retinal Bax/Bcl2 ratio (Fig. 7K–N) and a higher TUNEL-positive cell number in GCL (Fig. 7O, P), thereby diminishing the protective effect of the nanoparticles against COH-induced RGC injury. Taken together, these findings indicated that nanoparticles alleviated COH-related RGC damage by upregulating pAMPKThr172 expression and enhancing autophagic activity in RGCs.Fig. 7NP-CTB–mediated modulation of AMPK phosphorylation associated with RGC survival during COH. (A–B) Representative immunofluorescence images showing pAMPKThr172 in retinal sections from control and COH eyes at different time points after model induction, with quantification of pAMPKThr172 fluorescence intensity in the GCL. pAMPKThr172 is shown in magenta, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (C–D) Western blotting analysis of pAMPKThr172 expression in retinal tissues from control and COH eyes at different time points after model induction, with quantification of pAMPKThr172 protein levels. (E–G) Representative immunofluorescence images showing pAMPKThr172 expression in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of pAMPKThr172 fluorescence intensity in the GCL. Scale bar, 50 μm. (H–J) Western blotting analysis of pAMPKThr172 expression in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of pAMPKThr172 protein levels. (K–N) Western blotting analysis of pAMPKThr172, LC3-II, Bax, and Bcl2 in retinal tissues from COH rats pretreated with NP-CTB in the presence or absence of compound C and analyzed at day 14 after model induction, with quantification of pAMPKThr172, LC3-II, and the Bax/Bcl2 ratio. (O–P) Representative TUNEL-stained retinal sections from COH rats treated with NP-CTB in the presence or absence of compound C and analyzed at day 14 after model induction, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA (B, D) or unpaired Student’s t-test (F, G, I, J, L, M, N, P) and data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 NP-CTB–mediated modulation of AMPK phosphorylation associated with RGC survival during COH. (A–B) Representative immunofluorescence images showing pAMPKThr172 in retinal sections from control and COH eyes at different time points after model induction, with quantification of pAMPKThr172 fluorescence intensity in the GCL. pAMPKThr172 is shown in magenta, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. (C–D) Western blotting analysis of pAMPKThr172 expression in retinal tissues from control and COH eyes at different time points after model induction, with quantification of pAMPKThr172 protein levels. (E–G) Representative immunofluorescence images showing pAMPKThr172 expression in retinal sections from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of pAMPKThr172 fluorescence intensity in the GCL. Scale bar, 50 μm. (H–J) Western blotting analysis of pAMPKThr172 expression in retinal tissues from COH rats treated with NP-CTB either as a pretreatment or on the 7th day of COH, compared with NS-treated controls given in the same manner, with quantification of pAMPKThr172 protein levels. (K–N) Western blotting analysis of pAMPKThr172, LC3-II, Bax, and Bcl2 in retinal tissues from COH rats pretreated with NP-CTB in the presence or absence of compound C and analyzed at day 14 after model induction, with quantification of pAMPKThr172, LC3-II, and the Bax/Bcl2 ratio. (O–P) Representative TUNEL-stained retinal sections from COH rats treated with NP-CTB in the presence or absence of compound C and analyzed at day 14 after model induction, with quantification of TUNEL-positive cells in the GCL. TUNEL-positive cells are shown in green, and nuclei are counterstained with DAPI (blue). Scale bar, 50 μm. Statistical analysis was performed using one-way ANOVA (B, D) or unpaired Student’s t-test (F, G, I, J, L, M, N, P) and data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 Discussion In this study, we developed an RGC-targeted and ROS-responsive drug delivery system by incorporating CTB-modified selective uptake and an ROS-cleavable polymeric shell encapsulating the TRPV4 antagonist HC-067047. The nanoparticles were efficiently internalized by RGCs and released the drug specifically under COH-induced elevated ROS levels microenvironment. COH-induced TRPV4 activation contributes to Ca2+ dysregulation and impaired autophagic flux, which are key processes associated with RGC vulnerability. TRPV4 inhibition via the targeted delivery system restored impaired autophagic flux and significantly reduced COH-induced RGC injury. We previously identified that the TRPV4 antagonist HC-067047 offers potential neuroprotection in a rat COH model [15]. However, the intraocular targeted delivery and controlled release of this small-molecule compound still encounter multiple limitations [33]. Due to poor corneal drug penetration, topical administration allowed only a very small amount of the active components of eyedrops to reach the retina. Intravitreal injection can deliver drugs directly to the retina but involves notable risks of infection due to repeated punctures, and the lack of specificity makes it difficult to target RGCs, potentially causing adverse effects on other cells. To address these challenges, we developed a novel nanodrug delivery system in which the TRPV4 antagonist HC-067047 was encapsulated within an ROS-responsive shell that released the drug specifically in the high-ROS pathological microenvironment induced by COH. Simultaneously, CTB conjugation enabled targeted nanoparticle delivery to RGCs after intravitreal injection. By conjugating CTB to the nanoparticle surface, drugs could be precisely delivered to RGCs, thereby improving the efficiency of upregulating or suppressing key intracellular proteins. Meanwhile, the responsive design of the nanoparticle shell provides a new possibility for pathology-triggered precise release. Using ROS-sensitive materials enabled selective drug release within the oxidative stress microenvironment commonly present in glaucomatous RGCs, markedly enhancing drug efficacy while reducing off-target toxicity. Beyond glaucoma treatment, ROS-responsive nanoparticles have a wide range of applications. Ling et al. reported an ROS-responsive ordered assembly of magnetic nanoparticles (MNPs). By responding to ROS to regulate the assembly and disassembly of these ordered structures, MNPs achieved ROS-dependent MPI signal on/off regulation. MNPs enable monitor pathological ROS change in an early acute liver injury mice model,which is the first Application of Microenvironment-Responsive MPI Probes in the Early Diagnosis of ROS-Related Diseases [39]. Song et al. developed an ROS-driven gene-editing nanomotor (RDN@PL) that consumes ROS extracellularly while increasing ROS intracellularly, demonstrating a favorable tumor suppression rate [40]. Our results revealed that the NPCy5.5-CTB group exhibited markedly stronger Cy5.5 fluorescence in the optic nerve axonal layer and a significantly larger colocalization area with Tuj1 than NPCy5.5 and Cy5.5 solvent groups, indicating that CTB modification markedly enhanced the specificity and uptake efficiency of nanoparticles targeting RGCs. NP-CTB did not alter retinal TRPV4 expression under normal physiological conditions. However, under COH conditions, NP-CTB markedly reduced TRPV4 expression in the GCL on day 14 without affecting other retinal layers. Meanwhile, NP-CTB significantly reduced the TUNEL-positive cell number in GCL on day 14 of COH; however, no evident changes were observed in other retinal layers. These results demonstrated that NP-CTB markedly enhanced its protective efficacy toward RGCs compared to free HC-067047 at the same concentration and provided new strategies for neuroprotective treatment in glaucoma. Moreover, the RGC-targeted and pathology-responsive dual-design nanoparticles proposed in this study offer an effective tool for selective protein modulation in RGCs to assess the underlying molecular mechanisms. Autophagy is a key mechanism that maintains intracellular homeostasis and removes damaged organelles and abnormal proteins. However, whether autophagy plays a "protective" or "deleterious" role in COH-induced RGC injury remains undetermined. Some studies have suggested that excessive autophagy activation may aggravate the neuronal metabolic and energetic burden by excessively clearing essential organelles [27]. Other studies have proposed that insufficient autophagy prevents the timely removal of damaged organelles and misfolded proteins, thereby triggering persistent stress and inflammation that promote RGCs’ death [28]. To address this controversy, we measured autophagic flux in RGCs on days 7 and 14 in the COH model. The results revealed that autophagic flux was markedly elevated on day 7; however, it significantly declined by day 14. Notably, autophagic flux inhibition exacerbated RGC death on either day 7 or 14. Conversely, intraperitoneal administration of rapamycin restored autophagic flux and markedly improved RGCs survival on day 14. This dynamic pattern exhibited that autophagy may be activated as an adaptive and protective clearance mechanism during the early phase of COH to remove damaged structures. However, as the disease progresses, failure to maintain autophagic flux may lead to cumulative damage and accelerate RGC apoptosis. Consequently, in the COH-related RGC injury model, maintaining a moderate and stable autophagic flux may be more beneficial for neuronal survival. TRPV4 is a typical mechanosensitive cation channel that is aberrantly activated under COH conditions, leading to Ca2+ overload and cellular injury in RGCs. However, few studies had systematically delineated the relationship between TRPV4 activation and autophagic alterations in RGCs under COH. In this study, we used NP-CTB nanoparticles that specifically target RGCs to directly assess the regulatory network between TRPV4 and autophagy. The results revealed that NP-CTB enhanced autophagic flux in RGCs under COH conditions, specifically by promoting autophagic degradation on day 7 of COH and augmenting autophagy activation on day 14 of COH. The results exhibited that COH-induced TRPV4 activation markedly suppressed the autophagic flux in RGCs, which was particularly evident as insufficient autophagy activation on day 14. A similar phenomenon, in which TRPV4-mediated autophagy shifts from early adaptive activation to subsequent insufficiency, has also been reported in salt-induced cardiac hypertrophy models [41], suggesting that TRPV4 may participate in the dynamic regulation of autophagy across multiple chronic disease states. To further investigate the underlying mechanism by which NP-CTB protected RGCs by promoting autophagic flux in COH models, we examined the changes in pAMPKThr172, a Ca2+-regulated energy-sensing kinase essential for autophagy initiation, and the results revealed that pAMPKThr172 exhibited temporal dynamics consistent with autophagic flux (increased on day 7 and decreased on day 14), suggesting that it may serve as a key mediator through which TRPV4 perturbed autophagy. NP-CTB administration restored pAMPKThr172 expression, whereas co-treatment with the AMPK inhibitor compound C markedly attenuated the NP-CTB-induced enhancement of autophagy and reduction of apoptosis in RGCs on day 14 of COH, further demonstrating that activated TRPV4 impaired autophagy initiation by suppressing pAMPKThr172, thereby contributing to RGC injury. Combining our results with prior studies, we propose that COH-induced TRPV4 activation in RGCs leads to intracellular Ca2⁺ dysregulation, which in turn suppresses autophagy initiation and impairs lysosomal degradation, ultimately contributing to RGC death. Mechanistically,pathogenic TRPV4 activation caused persistent Ca2+ overload and neuronal injury [42, 43]. Persistent TRPV4-mediated Ca2⁺ overload activates Ca2⁺/calmodulin-dependent phosphatases such as calcineurin, resulting in dephosphorylation of AMPKThr172 and CaMKIIThr286 [44]. This dephosphorylation diminishes the positive regulation of autophagy-initiating platforms, including Beclin-1 and ULK1, thereby reducing autophagic flux [45], as reflected in our observed changes in LC3-II, p62, and LC3-LAMP1 colocalization in COH retinas. In parallel, TRPV4 activation impairs lysosomal acidification and hydrolase maturation, further inhibiting autophagic substrate degradation [31, 46, 47]. Collectively, these data support a model in which TRPV4-mediated Ca2⁺ dysregulation disrupts both the initiation and terminal phases of autophagy in RGCs, providing a mechanistic explanation for the progressive neurodegeneration observed under COH. This study has several limitations. First, as TRPV channels are among the members of the mechanosensitive ion channel families, they are important in mediating cellular responses to pressure signals in the eye. Therefore, it is unknown whether the delivery of other mechanosensitive ion channel (including Piezo-type mechanosensitive ion channel) antagonists can achieve the same or better protective effects. Second, although autophagic flux was assessed at the whole-cell level, organelle-specific autophagy was not directly investigated. Therefore, the specific roles of mitophagy and endoplasmic reticulum autophagy in RGC vulnerability under COH remain to be defined. Thirdly, polymeric nanoparticles may undergo rapid drug release within the body, leading to excessive local drug concentrations that fail to maintain stable therapeutic levels over extended periods, thereby compromising sustained therapeutic efficacy. Finally, previous studies demonstrated that aberrant activation of glia cells, including Müller glia and microglia, under COH conditions constituted a critical driving force for RGCs’ degeneration through diverse mechanisms [48, 49]. Accordingly, developing multitarget nanodelivery systems capable of acting on multiple retinal cell types and modulating several key signaling pathways simultaneously may achieve durable or more effective neuroprotective effects, which we will focus on and study in the future. Conclusions In this study, we developed a novel RGC-targeted and ROS-responsive drug delivery system by integrating a CTB-modified and ROS-responsive shell and encapsulating the TRPV4 antagonist HC-067047. These nanoparticles were specifically and efficiently internalized by RGCs and selectively released HC-067047 in a high ROS microenvironment induced by COH. TRPV4 inhibition by the targeted delivery system significantly attenuated COH-induced RGC damage compared with the free compound HC-067047, and this neuroprotective effect might be achieved by restoring autophagic flux in RGCs. This study provides a novel strategy for developing a drug delivery system for neuroprotective therapy in glaucoma and offers essential evidence for elucidating autophagic alterations in RGCs in COH models. Supplementary Information Additional file 1. Additional file 1.